Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy
A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85023
- Orthopedic Surgery Center
-
Phoenix, Arizona, United States, 85050
- Orthopedic Surgery Center
-
Tucson, Arizona, United States, 85712
- Orthopedic Surgery Center
-
-
California
-
Encinitas, California, United States, 92024
- Orthopedic Surgery Center
-
Laguna Hills, California, United States, 92653
- Orthopedic Surgery Center
-
Los Angeles, California, United States, 90045
- Orthopedic Surgery Center
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Orthopedic Surgery Center
-
-
Michigan
-
Royal Oaks, Michigan, United States, 48073
- Orthopedic Surgery Center
-
-
Minnesota
-
Bloomington, Minnesota, United States, 55431
- Orthopedic Surgery Center
-
Edina, Minnesota, United States, 55435
- Orthopedic Surgery Center
-
-
New York
-
Bronx, New York, United States, 10461
- Orthopedic Surgery Center
-
New York, New York, United States, 10003
- Orthopedic Surgery Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Orthopedic Surgery Center
-
-
Ohio
-
Columbus, Ohio, United States, 43221
- Orthopedic Surgery Center
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States, 16602
- Orthopedic Surgery Center
-
State College, Pennsylvania, United States, 16801
- Orthopedic Surgery Center
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Orthopedic Surgery Center
-
-
Washington
-
Seattle, Washington, United States, 98122
- Orthopedic Surgery Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Voluntarily provide written informed consent in accordance with governing Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements, local regulations, and Health Insurance Portability and Accountability Act (HIPAA) Authorization (or equivalent if locally applicable)
- In the opinion of the Investigator are able to comply with study-required visits and procedures
- 18 to 75 years of age, inclusive at the time of screening
- Have a traumatic or degenerative meniscal cartilage injury (full thickness tear) that occurred at least 14 days prior to the day of arthroscopic surgery that is demonstrated on MRI
- Planning to undergo unilateral arthroscopic meniscectomy
- If female and of childbearing potential (i.e., not surgically sterilized or post-menopausal for longer than one year), agree to use a medically accepted method of birth control for the duration of her study involvement
- At minimal risk from anesthesia and classified according to the American Society of Anesthesiologists Physical Status Classification as either PS-1 (a normal healthy patient) or PS-2 (a patient with mild systemic disease that results in no functional limitation) as determined by the Investigator.
Exclusion Criteria:
- Significant arthritis in the surgical knee (Grade 3 or 4 on the Kellgren- Lawrence Grading Scale).
- History of reactive synovial disease
- History of a complex regional pain syndrome (Type I, i.e., reflex sympathetic dystrophy, or Type II, i.e., causalgia), chronic pain, attendance at a chronic pain clinic, or neurologic disorder associated with sensory deficit of the lower extremities
- History of fibromyalgia
Expected to undergo any of the following procedures concurrent with the meniscectomy:
- Meniscal repair procedure
- Patellar tendon debridement
- Patellar realignment
- Lateral or retinacular release
- Excision synovectomy (minor synovectomy to improve arthroscopic visualization is allowed)
- Concurrent ligamentous procedure
- Abrasion chondroplasty involving bone
- Microfracture
- Chondral transplantation
- Use of more than three portals
- Known allergies to any of the individual ingredients in OMS103HP-S, other NSAIDs, aspirin, tricyclic antidepressants, or opioid analgesics
- Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
- Have a job-related claim(s) under dispute or mediation
- History of drug or alcohol abuse
- Treatment with an investigational drug or device within 30 days prior to the day of surgery
- A clinically significant medical condition that in the opinion of the Investigator would put the subject at increased risk, impair the subject's ability to comply with the requirements of the protocol, or confound the interpretation of the data
- Expected to receive a regional block for analgesia for this procedure
- Considered by the Investigator for any reason to be an unsuitable candidate for receipt of an investigational drug
- The Investigator, employee of the investigative site, and/or part of the Investigator/employee's immediate families (defined as current spouse or partner, parent, natural or legally adopted child, stepchild living in the household, grandparent, or grandchild).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: OMS103HP-S
OMS103HP-S injected into vehicle irrigation solution for administration during meniscectomy surgery
|
Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery
|
|
Placebo Comparator: Vehicle Irrigation Solution
|
3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
KOOS Symptoms Subscale
Time Frame: 30 days
|
To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on knee symptoms as measured by the KOOS Symptoms subscale through Day 30.
|
30 days
|
|
Safety
Time Frame: 90 days
|
To evaluate the safety of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on safety as measured by adverse events.
|
90 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knee Function in Sport Active patients
Time Frame: 30 Days
|
To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on knee function as measured by the KOOS Sports and Recreation subscale through Day 30 in the subset of subjects who participate in sports.
|
30 Days
|
|
Knee Pain
Time Frame: 30 days
|
To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on knee pain as measured by the KOOS Pain subscale through Day 30.
|
30 days
|
|
Quality of Life
Time Frame: 30 days
|
To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on knee quality of life as measured by the KOOS Quality of Life subscale through Day 30.
|
30 days
|
|
Knee Function
Time Frame: 30 days
|
To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on knee function as measured by the KOOS Activities of Daily Living subscale through Day 30.
|
30 days
|
|
Postoperative Knee Pain
Time Frame: Day of Surgery (day 1)
|
To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on postoperative knee pain as measured by the Visual Analog Scale during the day of surgery.
|
Day of Surgery (day 1)
|
|
Passive Flexion
Time Frame: 7 Days
|
To evaluate the effect of OMS103HP-S compared to vehicle when administered in joint irrigation fluid during arthroscopic meniscectomy on Passive flexion on Day 7.
|
7 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Steve Whitaker, MD, Omeros Corporation
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- OMS103-MEN-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.